XTL Biopharmaceuticals Ltd.
corporate_fare Company Profile
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for XTLB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for XTLB spans 6-K, 20-F.
Recent high-impact activity:
- XTL Sets Dec 28 Vote on $1M Related-Party Placement, New CEO and Psyga Name Change
- XTL Reports H1 2026 Loss of $899K; Discloses Psyga Deal, $1.5M Placement and New Derivative Claim
- Derivative Claim Targets XTL Biopharmaceuticals Over Failed Social Proxy Acquisition
- XTL Biopharmaceuticals Regains Full Nasdaq Compliance, Resolving Multiple Delisting Threats
- XTL Biopharmaceuticals Files Delayed 20-F, Reveals Going Concern Warning, Negative Equity, and Major Business Pivot to Psychedelic Therapeutics Amidst Nasdaq Delisting Risk
Financial Snapshot
Short Interest & Short Volume
1.05 days to coverFINRA reported short interest of 4,271 shares in XTLB as of the October 30, 2026 settlement, a 2.2% increase from the prior period — about 1.1 days to cover at its recent average daily volume. On November 20, 2026, 0.2% of XTLB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for XTLB, detected from its recent SEC filings · based on capital-structure filings through 2026-11-20.
Related-Party Placement Up to $1M · Warrant Reset Adds Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
XTLB files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.